pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,996 catalysts · 4,876 phase readout · 2,356 8k filing · 286 earnings · 275 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 18 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,356
  • earnings286
  • pdufa275
  • phase 2 completion166
  • phase 1 completion71
  • phase 2 initiation54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026phase 1 completion88d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoBio-Innova Co Ltd — febuxostat (Phase I Trial Initiation)febuxostat

    Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Gouty Arthritis (Gout), Hyperuricemia

    full page →febuxostat →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoNovo Nordisk AS — cagrilintide hydrochloride (Phase I Trial Initiation)cagrilintide hydrochloride

    Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

    full page →cagrilintide hydrochloride →source: globaldata
    ›Apr 28, 2026phase 1 initiation88d agoOvid Therapeutics Inc — OV-4071 (Phase I Trial Initiation)OV-4071

    Therapy area: Central Nervous System. Indication: Parkinson's Disease

    full page →OV-4071 →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoChangzhou Hengbang Pharmaceutical Co Ltd — HS-10374 (Phase II Trial Completion)HS-10374

    Therapy area: Musculoskeletal Disorders. Indication: Psoriatic Arthritis

    full page →HS-10374 →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoKS Hegde Medical Academy — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Hormonal Disorders. Indication: Endocrine Gland Disorders

    full page →fentanyl ER →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoUmraniye Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoAnanta Institute of Medical Sciences and Research Centre — levobupivacaine (Phase II Trial Completion)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoGastroenterological Association of Thailand — metadoxine (Phase II Trial Completion)metadoxine

    Therapy area: Gastrointestinal. Indication: Metabolic and Alcohol-Associated Liver Disease (MetALD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →metadoxine →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoTianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)AG [gemcitabine + nab-paclitaxel]

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →AG [gemcitabine + nab-paclitaxel] →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoHackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoTamilnadu Government Dental College and Hospital — metformin (Phase II Trial Completion)metformin

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →metformin →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoArdabil University of Medical Sciences — chorionic gonadotropin (Phase II Trial Completion)chorionic gonadotropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →chorionic gonadotropin →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoShanghai Pulmonary Hospital — undisclosed programmed cell death protein 1 inhibitor (Phase II Trial Completion)undisclosed programmed cell death protein 1 inhibitor

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →undisclosed programmed cell death protein 1 inhibitor →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoAl-Mustansiriya University — platelet rich fibrin (Phase II Trial Completion)platelet rich fibrin

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →platelet rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoWest China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Mouth and Dental Disorders. Indication: Aphthous Ulcers (Canker Sores)

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026phase 2 completion88d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoSRM Medical College Hospital and Research Centre — dexmedetomidine (Phase II Trial Initiation)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Unspecified Central Nervous System Disorders

    full page →dexmedetomidine →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoFudan University Shanghai Cancer Center — YZJ-2440 (Phase II Trial Initiation)YZJ-2440

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor

    full page →YZJ-2440 →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoShanxi Ruifulai Pharmaceutical Co Ltd — brexpiprazole (Phase II Trial Initiation)BREXPIPRAZOLE

    Therapy area: Central Nervous System. Indication: Schizophrenia

    full page →BREXPIPRAZOLE →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoAP Biosciences Inc — B-1962 (Phase II Trial Initiation)B-1962

    Therapy area: Oncology. Indication: Solid Tumor

    full page →B-1962 →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoRise Biopharmaceutical Ltd — RP-72 (Phase II Trial Initiation)RP-72

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer

    full page →RP-72 →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoInstitute of Medical Sciences of the Banaras Hindu University — ropivacaine (Phase II Trial Initiation)ropivacaine ER

    Therapy area: Central Nervous System, Respiratory. Indication: Pleural Disease, Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 28, 2026phase 2 initiation88d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 28, 2026phase 2 3 completion88d agoFaculty of Medicine Siriraj Hospital Mahidol University — bevacizumab (Phase II/III Trial Completion)bevacizumab

    Therapy area: Non Malignant Disorders. Indication: Hemangiomas

    full page →bevacizumab →source: globaldata
    ›Apr 28, 2026phase 2 3 completion88d agoFaculty of Medicine, Srinakharinwirot University — tranexamic acid (Phase II/III Trial Completion)tranexamic acid

    Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

    full page →tranexamic acid →source: globaldata
    ›Apr 28, 2026phase 2 3 initiation88d agoAyurved Mahavidyalaya and Shri Sant Eknath Rugnalaya. Shevgaon, — ayurvedic medicine (Phase II/III Trial Initiation)ayurvedic medicine

    Therapy area: Ear Nose Throat Disorders. Indication: Acute Tonsillitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 28, 2026phase 3 completion88d agoGovernment Stanley Medical College Hospital — tenecteplase (Phase III Trial Completion)tenecteplase

    Therapy area: Genito Urinary System, Infectious Disease. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Unspecified Bacterial Infections

    full page →tenecteplase →source: globaldata
    ›Apr 28, 2026phase 3 completion88d agoAll India Institute of Medical Sciences — (iron + folic acid) (Phase III Trial Completion)(iron + folic acid)

    Therapy area: Hematological Disorders. Indication: Anemia, Iron Deficiency Anemia

    full page →(iron + folic acid) →source: globaldata
    ›Apr 28, 2026phase 3 completion88d agoSun Yat-sen Memorial Hospital — capecitabine (Phase III Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Nasopharyngeal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 28, 2026phase 3 results88d agoBanook Group — brepocitinib tosylate (Phase III Trial Results)brepocitinib tosylate

    Therapy area: Musculoskeletal Disorders. Indication: Dermatomyositis

    full page →brepocitinib tosylate →source: globaldata
    ›Apr 28, 2026phase iv trial initiation88d agoDr Susheela Tiwari Government Hospital — ormeloxifene (Phase IV Trial Initiation)ormeloxifene

    Therapy area: Central Nervous System, Non Malignant Disorders. Indication: Benign Tumor, Mastalgia (Breast Pain)

    full page →ormeloxifene →source: globaldata
    ›Apr 28, 2026phase iv trial initiation88d agoRajendra Institute of Medical Sciences — levobupivacaine (Phase IV Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System. Indication: Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 20268k filing88d ago$JNJ — JOHNSON & JOHNSON (JNJ) — 8-K filing

    Items: 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$GNPX — Genprex, Inc. (GNPX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$PASG — Passage BIO, Inc. (PASG) — 8-K filing

    Items: 2.05

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$ACRS — Aclaris Therapeutics, Inc. (ACRS) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$INCY — INCYTE CORP (INCY) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$AVTX — Avalo Therapeutics, Inc. (AVTX) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$IMUX — IMMUNIC, INC. (IMUX) — 8-K filing

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$SGMT — Sagimet Biosciences Inc. (SGMT) — 8-K filing

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$ELAB — PMGC Holdings Inc. (ELAB) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$KNSA — Kiniksa Pharmaceuticals International, plc (KNSA) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$WVE — Wave Life Sciences Ltd. (WVE) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d agoROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing88d ago$SNGX — SOLIGENIX, INC. (SNGX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ← prev
    page 5 of 160
    next →
    $OVID2.3250-3.13%